Critical Comparison: Juniper Pharmaceuticals (JNP) and Its Peers

Juniper Pharmaceuticals (NASDAQ: JNP) is one of 115 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Juniper Pharmaceuticals to similar companies based on the strength of its dividends, valuation, earnings, risk, institutional ownership, analyst recommendations and profitability.


This table compares Juniper Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Juniper Pharmaceuticals 13.94% 21.49% 14.40%
Juniper Pharmaceuticals Competitors -2,882.43% -67.86% -8.82%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Juniper Pharmaceuticals and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Juniper Pharmaceuticals 0 1 2 0 2.67
Juniper Pharmaceuticals Competitors 816 3669 6686 180 2.55

Juniper Pharmaceuticals currently has a consensus price target of $23.00, suggesting a potential upside of 364.65%. As a group, “Pharmaceuticals” companies have a potential upside of 22.21%. Given Juniper Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Juniper Pharmaceuticals is more favorable than its peers.

Institutional and Insider Ownership

36.2% of Juniper Pharmaceuticals shares are held by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.6% of Juniper Pharmaceuticals shares are held by company insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Juniper Pharmaceuticals has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Juniper Pharmaceuticals’ peers have a beta of 0.90, meaning that their average stock price is 10% less volatile than the S&P 500.

Earnings & Valuation

This table compares Juniper Pharmaceuticals and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Juniper Pharmaceuticals $57.69 million $9.49 million 6.69
Juniper Pharmaceuticals Competitors $8.17 billion $2.69 billion -0.32

Juniper Pharmaceuticals’ peers have higher revenue and earnings than Juniper Pharmaceuticals. Juniper Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


Juniper Pharmaceuticals beats its peers on 7 of the 13 factors compared.

Juniper Pharmaceuticals Company Profile

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.

Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply